890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Temsirolimus Neoplasm	Miller Children's & Women's Hospital Long Beach	P1/2	B (60)
Tlx-101-Tx Neoplasm	Telix Pharmaceuticals (Innovations) Pty Limited	P3	B (60)
Toripalimab Neoplasm	Suzhou Abogen Biosciences Co., Ltd.	P2	B (60)
Trametinib Neoplasm	Cancer Research UK	P4	B (60)
Trastuzumab Deruxtecan Neoplasm	Lei Zheng	P2	B (60)
Vinorelbine Ditartrate Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
Zanidatamab Neoplasm	Haihua Yuan	P2	B (60)
Cis-Diamminedichloroplatinum Ii Neoplasm	Mabwell (Shanghai) Bioscience Co., Ltd.	P3	B (59)
Cobimetinib Neoplasm	Helsinki University Central Hospital	P2	B (59)
Fluorouracilum Neoplasm	Mirati Therapeutics Inc.	P3	B (59)
Lapatinib Neoplasm	Deraya University	P2	B (59)
Methoxyamine Neoplasm	National Cancer Institute (NCI)	P1/2	B (59)
Mitoxantrone Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	B (59)
Oxaliplatin Neoplasm	Mirati Therapeutics Inc.	P3	B (59)
Talazoparib Neoplasm	Pfizer	P3	B (59)
Veliparib Neoplasm	National Cancer Institute (NCI)	P1/2	B (59)
Binimetinib Neoplasm	Pfizer	P4	B (58)
Capecitabine Neoplasm	I-Mab Biopharma US Limited	P3	B (58)
Dabrafenib Neoplasm	Cancer Research UK	P4	B (58)
Diphenhydramine Neoplasm	Hellenic Society of Hematology	P2	B (58)
Docetaxel Neoplasm	Mirati Therapeutics Inc.	P3	B (58)
Dostarlimab Neoplasm	GlaxoSmithKline	P2	B (58)
Encorafenib Neoplasm	Pfizer	P4	B (58)
Entrectinib Neoplasm	Cancer Research UK	P2/3	B (58)
Everolimus Neoplasm	Uppsala University Hospital	P2	B (58)
Ibrutinib Neoplasm	National University Hospital, Singapore	P4	B (58)
Nelistotug (Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd96 (T Cell Activation Increased Late Expression, Tactile, T-Cell Surface Protein Tactile)], Homo Sapiens Monoclonal Antibody) Neoplasm	GlaxoSmithKline	P2	B (58)
Niraparib Neoplasm	GlaxoSmithKline	P2	B (58)
Olaparib Neoplasm	Hebei Medical University Fourth Hospital	P3	B (58)
Pazopanib Neoplasm	Tianjin Medical University Second Hospital	P2	B (58)
Pelabresib Neoplasm	Novartis Pharmaceuticals	P3	B (58)
Pembrolizumab Neoplasm	Mirati Therapeutics Inc.	P3	B (58)
Trastuzumab Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P3	B (58)
Vorolanib Neoplasm	Li-kun Chen	P2	B (58)
Acetylcysteine Neoplasm	Fakultas Kedokteran Universitas Indonesia	P2/3	B (57)
Axitinib Neoplasm	Yonsei University	P3	B (57)
Azacitidine Neoplasm	National University Hospital, Singapore	P1/2	B (57)
Cabozantinib Neoplasm	Arcus Biosciences, Inc.	P2	B (57)
Catequentinib Neoplasm	Sun Yat-sen University	P2	B (57)
Ezabenlimab Neoplasm	Boehringer Ingelheim	P2	B (57)
Neratinib Neoplasm	Memorial Sloan Kettering Cancer Center	P2	B (57)
Rvp-001 Neoplasm	Reveal Pharmaceuticals Inc.	P2	B (57)
Ulixertinib Neoplasm	BioMed Valley Discoveries, Inc	P2	B (57)
Eribulin Monomethanesulfonate Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (56)
Incb161734 Neoplasm	Incyte Corporation	P3	B (56)
Ipatasertib Neoplasm	Hoffmann-La Roche	P2	B (56)
Obinutuzumab Neoplasm	M.D. Anderson Cancer Center	P2	B (56)
Plixorafenib Neoplasm	Fore Biotherapeutics	P2	B (56)
Propofol Neoplasm	Hong Kong Children's Hospital	P4	B (56)
Pyrotinib Neoplasm	InxMed (Shanghai) Co., Ltd.	P2	B (56)

Showing 51 to 100 of 890 assets

PreviousPage 2 of 18Next